Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC
Some patients develop more advanced cancer that requires surgery, often on exposed surfaces like the scalp, face, or neck.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Novel Hormonal Agents Studied in High - Risk Prostate Cancer
Neoadjuvant therapy with an NHA associated with longer time to biochemical recurrence, prolonged metastasis - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 22, 2022 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Surgery, Urology, Journal, Source Type: news
Neoadjuvant Novel Hormonal Agents Studied in High-Risk Prostate Cancer
THURSDAY, Sept. 22, 2022 -- Neoadjuvant therapy with a novel hormonal agent prior to radical prostatectomy is associated with better outcomes for men with high-risk prostate cancer versus upfront radical prostatectomy, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 22, 2022 Category: Pharmaceuticals Source Type: news
Response to Neoadjuvant Endocrine Therapy for Breast Cancer May Vary by Race
TUESDAY, Sept. 20, 2022 -- The response to neoadjuvant endocrine therapy (NET) for hormone receptor-positive breast cancer (HR+BC) may vary by race, according to a study presented at the 15th AACR Conference on the Science of Cancer Health... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
No increased perioperative morbidity seen among patients with local regionally advanced oral cavity squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Surgery, Journal, Source Type: news
FDG - PET May Predict Response to Neoadjuvant Therapy in Pancreatic Cancer
Preoperative FDG - PET may predict pathologic response to neoadjuvant therapy for borderline resectable/locally advanced PDAC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Radiology, Journal, Source Type: news
Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC
THURSDAY, Sept. 15, 2022 -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news
FDG-PET May Predict Response to Neoadjuvant Therapy in Pancreatic Cancer
THURSDAY, Sept. 15, 2022 -- For patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC), preoperative fluorodeoxyglucose positron emission tomography (FDG-PET) may predict pathologic response to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma
(MedPage Today) -- PARIS -- The randomized trial data have spoken, and they favor neoadjuvant immunotherapy over adjuvant treatment for resectable melanoma.
Neoadjuvant pembrolizumab (Keytruda) followed by surgery and additional pembrolizumab... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2022 Category: Hematology Source Type: news
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma
(MedPage Today) -- PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous squamous cell carcinoma (cSCC), according to research presented here.
Among 79 patients treated... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 13, 2022 Category: Dermatology Source Type: news
Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
MONDAY, Sept. 12, 2022 -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for resectable stage II, III, or IV (M0) cutaneous squamous cell carcinoma had a pathological complete response, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2022 Category: Pharmaceuticals Source Type: news
'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO
(MedPage Today) -- PARIS -- Nearly every single patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response with just two cycles of neoadjuvant immunotherapy.
Patients in the single-arm study... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 12, 2022 Category: Gastroenterology Source Type: news
Not Just What, But When: Neoadjuvant Pembrolizumab in Melanoma Not Just What, But When: Neoadjuvant Pembrolizumab in Melanoma
New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
' Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer
An ' innovative ' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved ' unprecedented ' pathologic responses, with no recurrences.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Galunisertib Added to Standard Treatment Promising in Rectal Cancer
(MedPage Today) -- Adding the investigational TGF-β type I receptor kinase inhibitor galunisertib to neoadjuvant chemoradiotherapy was associated with improved response rates in patients with locally advanced rectal cancer compared with historical... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 3, 2022 Category: Gastroenterology Source Type: news
